Table 3.
Factors affecting long-term clinical outcomes.
| (A) Factors affecting overall survival (OS) | ||||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Age>60 vs. ≤60 yr | 20.372 | 3.466–119.724 | 0.001 | 61.945 | 5.675–676.201 | 0.001 |
| ECOG PS>1 vs. ≤1 | 10.429 | 2.851–38.155 | <0.001 | 21.384 | 2.851–160.369 | 0.003 |
| LDH, increased vs. normal | 7.408 | 2.381–23.049 | 0.001 | 6.576 | 1.655–26.139 | 0.007 |
| High ADC vs. low ADC | 0.273 | 0.103–0.721 | 0.009 | 0.392 | 0.155–0.854 | 0.012 |
| Size≥5 cm vs. <5 cm | 2.694 | 0.931–7.794 | 0.067 | |||
| (B) Factors affecting failure-free survival (FFS) | ||||||
| Univariate | Multivariate | |||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Age>60 vs. ≤60 yr | 4.227 | 1.597–11.192 | 0.004 | |||
| ECOG PS>1 vs. ≤1 | 4.278 | 1.305–14.017 | 0.016 | 10.319 | 1.428–74.551 | 0.021 |
| LDH, increased vs. normal | 1.839 | 0.882–3.831 | 0.099 | |||
| Enhancement, homogenous vs. non-homogenous | 0.401 | 0.193–0.834 | 0.014 | |||
| Necrosis, presence vs. absence | 4.610 | 2.151–9.876 | <0.001 | 6.372 | 1.609–25.235 | 0.008 |
| High ADC vs. low ADC | 0.432 | 0.210–0.888 | 0.022 | 0.226 | 0.065–0.792 | 0.020 |
| T2-weighted imaging, hyperintense signal vs. isointense signal | 0.289 | 0.128–0.650 | 0.003 | |||
Abbreviations: ADC, apparent diffusion coefficient; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase.